New Limit closes $130M Series B to advance epigenetic reprogramming medicines for liver disease and aging

Summary

New Limit, co-founded by Jacob Kimmel, is building what it describes as a new class of medicine aimed at extending human health span through epigenetic reprogramming. The company closed a $130 million Series B to advance that work, with its most mature program targeting liver disease.

The science

The core premise is that aging degrades the epigenetic marks that tell cells which genes to activate. As those marks deteriorate, cells lose functional precision, which Kimmel argues precipitates a range of age-related diseases. New Limit's bet is that you can chemically reset those marks back to a younger state — and that doing so could restore tissue function and resilience.

The technology wasn't viable even a decade ago. Two enabling developments made it tractable: single-cell genomics, which lets researchers sequence the RNA activity of individual cells, and AI, which lets the company prioritize which reprogramming interventions are worth testing. The search space is enormous — roughly 10^16 possible combinations, a number Kimmel compares to 10,000 Milky Ways worth of stars. New Limit can run about 14,000 experiments, so AI-driven prioritization is load-bearing, not optional.

Before New Limit existed, only 19 epigenetic reprogramming interventions had ever been attempted in the field. Kimmel says he personally ran 16 of them in his prior lab. New Limit has now tested around 14,000 approaches — roughly 700x the prior field-wide total.

Pre-clinical proof of concept

The milestone that unlocked this round, and arrived faster than the team expected, was a pre-clinical proof of concept. New Limit produced drug-like molecules — actual compounds you can hold in a tube — and demonstrated efficacy in two settings. In human liver cells taken from older donors, the molecules restored regenerative function to levels typical of younger cells. In animal models of alcohol-related liver disease, the compounds both improved regeneration and increased cellular resilience to alcohol-induced damage. Kimmel describes this as the first time anyone has produced a reprogramming medicine with that combination of drug-like properties and demonstrated efficacy.

Use of the $130M

The capital goes primarily toward R&D across three therapeutic programs. The lead program targets liver disease, with an ambition to eventually treat the broader metabolic decline that affects more than half the population as they age — elevated rates of heart attack, diabetes, and obesity. Compute costs exist but are not yet near $100 million; the company's data generation scale is what Kimmel expects will eventually drive that number up. The downstream path follows standard FDA drug development: animal trials, then human clinical trials across phases one through three.

The commercial logic

Kimmel is candid that biotech milestones are harder to read than SaaS revenue for years at a stretch. The counterpoint he offers is that the upside is asymmetric: more drugs generate over a billion dollars in annual revenue today than software companies do. A single successful product is transformational, which is what makes the long, opaque development timeline worth tolerating for investors willing to hold through it.